|1.||Davis, Joseph: 1 article (10/2010)|
|2.||Chappel, Scott: 1 article (10/2010)|
|3.||Catherino, William H: 1 article (10/2010)|
|4.||Segars, James: 1 article (10/2010)|
|5.||Malik, Minnie: 1 article (10/2010)|
|6.||Driggers, Paul: 1 article (10/2010)|
|1.||Leiomyoma (Uterine Fibroids)
10/01/2010 - "CP8947 was a potent novel non-steroidal SPRM that was selective for PR, demonstrated progestational activity in endometrium, inhibited leiomyoma cell proliferation and decreased ECM component production, without disrupting myometrial cell proliferation."
10/01/2010 - "Nanomolar CP8947 treatment inhibited human leiomyoma but not myometrial cell proliferation. "
10/01/2010 - "Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium."
10/01/2010 - "The goal of these studies was to determine the progesterone receptor (PR) specificity and activation, endometrial response, and impact on leiomyoma cell proliferation and extracellular matrix (ECM) production of the novel non-steroidal selective progesterone receptor modulators (SPRMs) CP8863 and CP8947. "
10/01/2010 - "Both compounds induced alkaline phosphatase comparably to progesterone, while CP8947 induced ER-α in leiomyoma cells but not myometrial cells. "
|1.||Progesterone Receptors (Progesterone Receptor)